Beth Seidenberg Joins Kleiner Perkins Caufield & Byers to Advance Innovation in Science into the Healthcare Arena.

MENLO PARK, Calif. -- Kleiner Perkins Caufield & Byers -- an innovator in providing "venture and relationship capital"(SM) services to entrepreneurs -- is pleased to announce Beth Seidenberg has joined the KPCB team as an Executive in Residence.

"Innovation in life sciences is accelerating and providing important opportunities to translate science from the laboratory into the clinic -- making this a great time for entrepreneurs and for me to join KPCB," said Seidenberg. "I look forward to working with entrepreneurs and the KPCB team to produce life-changing medical breakthroughs."

Brook Byers of KPCB said, "Beth's background and senior level experience at Amgen, Bristol Myers Squibb, Merck and the NIH are a perfect fit with our strategic initiatives. Beth will immediately add value by sharing her knowledge, wisdom and network with the management teams of our exciting life sciences companies. She also has fresh ideas about translational medicine that can lead to exciting startups."

Seidenberg added, "I have dedicated my career to introducing new innovative treatments for patients and thereby changing the practice of medicine. My passion is working with talented teams to take novel scientific discoveries from the laboratory to the bedside. I am thrilled with the opportunity to work with talented and visionary entrepreneurs who will improve the lives of large numbers of patients."

Roger Perlmutter, M.D., Ph.D., Executive Vice President of Amgen, said "Beth is the consummate drug development professional, a brilliant tactician with a keen grasp of what is required to build blockbuster products. Having worked closely with her for nearly a decade, I am delighted she is bringing her energy, industry and powerful business skills to KPCB."

Beth was the Senior Vice President, Global Development and Chief Medical Officer at Amgen, Inc., where she had responsibility for all stages of clinical research, regulatory affairs, safety, health economics/reimbursement and medical affairs, and managed over 1,500 employees. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb Company and Merck & Co., Inc. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases.

Seidenberg, 48, has a Bachelors degree in Biology from Barnard College Magna Cum Laude, Phi Beta Kappa; and a medical degree from the University of Miami Leonard M. Miller School of Medicine, Alpha Omega Alpha. Her post-graduate training was completed at Johns Hopkins School of Medicine, George Washington School of Medicine and Health Sciences and the National Institutes of Health.

Since its founding in 1972, KPCB has backed entrepreneurs in 450 ventures, including AOL, Align, Amazon.com, Citrix, Compaq Computer, Electronic Arts, Genentech, Genomic Health, Genprobe, Google, Hybritech, IDEC Pharmaceuticals, Intuit, Juniper Networks, Netscape, Ligand Pharmaceuticals, Lotus, Nuvasive, Sun Microsystems, Symantec, Verisign and Xilinx. KPCB portfolio companies employ more than 250,000 people. More than 150 of the firm's portfolio companies have gone public. Many other ventures have achieved success through mergers and acquisitions.